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Abstract Gastroenteropancreatic neuroendocrine tumors
(GEP-NETs) are a family of neoplasms with a complex spec-
trum of clinical behavior. Although generally more indolent
than carcinomas, once they progress beyond surgical resect-
ability, they are essentially incurable. Systemic treatment op-
tions have substantially expanded in recent years for the man-
agement of advanced disease. Imaging plays a major role in
new drug development, as it is the main tool used to objec-
tively evaluate response to novel agents. However, current
standard response criteria have proven suboptimal for the as-
sessment of the antiproliferative effect of many targeted
agents, particularly in the context of slow-growing tumors
such as well-differentiated NETs. The aims of this article are
to discuss the advantages and limitations of conventional ra-
diological techniques and standard response assessment
criteria and to review novel imaging modalities in develop-
ment as well as alternative cancer- and therapy-specific
criteria to assess drug efficacy in the field of GEP-NETs.
Keywords Neuroendocrine tumors . Response assessment .
Response criteria . Radiological evaluation . Functional
imaging
1 Introduction
Neuroendocrine tumors (NETs) of the gastroenteropancreatic
tract (GEP) are a family of neoplasms with a complex spec-
trum of clinical behavior. GEP-NETs arise from disseminated
endocrine cells that can store and secrete amines in response to
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different stimuli. The broad anatomical location and heteroge-
neous biology of GEP-NETs makes their clinical management
particularly challenging [1]. Treatment approaches include
surgery, locoregional liver-directed therapy, peptide receptor
radionuclide therapy (PRRT), and systemic hormonal, cyto-
toxic, or targeted therapy. Disease localization and extent, re-
sectability of the primary and metastatic disease, tumor biol-
ogy and dynamics, presence or absence of tumor somatostatin
receptors, local expertise and availability of therapeutic op-
tions (e.g., PRRT), clinical symptoms, personal preferences,
and the patient’s overall health condition are all key factors to
properly design an adequate customized treatment plan for
each patient.
Treatment options for GEP-NETs have substantially in-
creased in recent years, particularly in the area of systemic
medical therapy for advanced disease [2]. Imaging plays a
major role in new drug development, as it is the primary tool
used to objectively assess tumor response to novel agents.
However, current standard response assessment criteria—Re-
sponse Evaluation Criteria In Solid Tumors (RECIST) [3,
4]—were originally developed to measure cytotoxic chemo-
therapy efficacy in solid tumors and are suboptimal to evaluate
the antiproliferative effects of many new cytostatic agents,
particularly in slow-growing tumors such as well-
differentiated GEP-NETs. In fact, several agents (i.e.,
octreotide, lanreotide, sunitinib, and everolimus) induce few,
if any, objective responses according to the conventional
criteria, but significantly delay tumor growth thereby improv-
ing progression-free survival (PFS) of patients [5–8]. To ad-
dress the limitations of RECIST, a number of alternative re-
sponse criteria have been proposed for specific types of cancer
and therapeutic agents or strategies. At the same time, the
extraordinary advances achieved in the field of functional im-
aging are providing new means for assessing the antitumor
activity of different therapeutic approaches. This article aims
to discuss the advantages and limitations of current standard
radiological techniques and response assessment criteria and
to review new imaging modalities that are being developed as
well as alternative cancer- and therapy-specific criteria to eval-
uate drug efficacy in the field of GEP-NETs.
2 Imaging assessment of tumor response
2.1 Conventional imaging modalities
Morphological and functional imaging techniques are crucial
for characterizing and managing GEP-NETs in clinical prac-
tice. Various different imaging modalities are used for screen-
ing at-risk populations, detecting primary lesions, assessing
the extent of the disease, and evaluating the patient’s response
to treatment [5, 9–11]. The choice of which techniques to use
depends on clinical presentation and specific tumor features,
including location, somatostatin receptor expression, func-
tionality, and proliferation rate [10]. Currently, GEP-NETs
are morphologically assessed by computed tomography
(CT) and magnetic resonance imaging (MRI). Additionally,
various ultrasound (US) approaches (transabdominal, endo-
scopic, and intraoperative) can be useful for detecting certain
primary tumors (e.g., pancreatic) or liver metastasis (Table 1).
CT is the most commonly used technique for initial tumor
localization, staging, therapeutic monitoring, and follow-up of
patients with GEP-NETs. Its rapid acquisition process and
ability to generate multiplanar reconstructions provide high
temporal and spatial resolution (20–200 μm; pixel/voxel di-
mension <1 mm), which improve the probability of detection
(Fig. 1). Curved reformats, three-dimensional volume render-
ing techniques and maximum intensity projection provide im-
portant anatomic details for surgical planning (e.g., tumor vas-
cular encasement). CT scan also effectively detects nodal and
metastatic disease. The majority of GEP-NETs are visible as
enhanced or hypervascular lesions and are typically more con-
spicuous in the late arterial acquisition phases [12]. On
precon t ras t images , these les ions are typ ica l ly
hypoattenuating, although some primary lesions may be small
and have the same density as normal parenchyma and thus
may be difficult to detect. It is therefore crucial to perform
multiphasic contrast-enhanced CT, including arterial and por-
tal venous acquisition phases. Indeed, the differences in the
time elapsed after contrast administration may substantially
affect image acquisition, potentially leading to both false-
positive or false-negative findings that can result in an errone-
ous detection or response assessment. Particular caution is
recommended regarding clinical decisions based on the emer-
gence or fading of a single small lesion. The sensitivity of
multidetector CT for primary pancreatic GEP-NETs ranges
from 57 to 63 % and may be as high as 94 % if CT slices
are reformatted in thin sections (1–1.5 mm). This detection
rate substantially decreases, however, for primary
extrapancreatic tumors, particularly those located in the small
bowel. Some of these tumors may be only visible when mes-
entery involvement induces surrounding fibrosis
(desmoplastic reaction) with tissue retraction. More recently,
a novel modality, dual-energy CT (DECT), is an emerging
technique based on imaging at two distinctly different energy
levels (e.g., 80 and 140 kVp) to differentiate materials. DECT
can provide multiple parameters, including monochromatic
CT images, iodine-based material decomposition images and
spectral HU curves, and virtual unenhanced images, which
may add useful tissue information for detecting GEP-NETs
[13, 14].
MRI has also high spatial resolution (10–500 μm; pixel/
voxel dimension >1 mm) and offers several advantages over
CT scans, including the lack of ionizing radiation, superior
soft tissue discrimination, and greater interobserver agree-
ment. In addition, MRI offers the advantage of combining
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Table 1 Main morphological and functional imaging modalities available to evaluate response to treatment in patients with GEP-NETs
Imaging
modality
Principle/target Mechanism/radiotracer Biological correlation Advantages Limitations
US Tissue perfusion and
vascularity:
– Blood flow
– Peak intensity
– Time to peak intensity
– Area under the curve
DCE: enhanced
representation of the
vasculature following
the administration of
microbubbles
– No ionizing radiation
– Real-time imaging
– Short acquisition time
– Inexpensive
– Availability
–Whole-body imaging
not possible
– Contrast agents are
limited to vasculature
– Operator dependency
– Assessment limited to
selected targets
CT Tissue perfusion and
vascularity:
– Relative blood volume
– Relative blood flow
–Mean transit time
DCE: changes in density
following the
administration of
iodinated contrast
agent
– Vessel density
– Vascular
permeability
– Perfusion
– High spatial resolution
– Short acquisition time
–Moderately expensive
– Availability
– Radiation burden
– Poor soft tissue
contrast
– Assessment limited to
selected targets
MRI Tissue perfusion and
vascularity:
– Initial curve under the
gadolinium curve
– Transfer rate and
constants
– Leakage space fraction
– Fractional plasma
volume
DCE: contrast average
uptake rate in tissues
Influenced by transfer
rate, extracellular
volumes, plasma
volume fraction
– Vessel density
– Vascular
permeability
– Perfusion
– Tissue cell fraction
– Plasma volume
– No ionizing radiation
– Excellent soft tissue
contrast
– Expensive
– Long acquisition time
– Low availability
– Assessment limited to
selected targets
– Good patient
cooperation required
Scintigraphy SSTR2 111In-pentetreotide – SSTR2 density –Whole-body scan possible
– Availability
– Sensitivity and specificity
for staging superior to
conventional imaging
– High to moderate
affinity to SSTR2
– Low resolution; planar
views
– Long acquisition time
– Evaluation of organs
with high physiological
uptake (e.g., liver, gut)
SPECT or
SPECT/CT
SSTR2 111In-pentetreotide – SSTR2 density – Tomographic imaging
– Combines functional
and structural information
(SPECT/CT)
– Lower spatial resolution
than PET
– Long acquisition time
– Suboptimal physical
resolution of isotopes
used for SPECT
PET/CT SSTR2 68Ga-DOTA-TATE – SSTR2 density –Whole-body scan possible
– High spatial resolution
of PET
– Short acquisition time
– Very high affinity to SSTR
– Rapid extraction and
clearance
– Combines functional and
structural information
– Limited to SSTR2
expression
– Tumor dedifferentiation
and loss of SSTR
expression
SSTR2, SSTR5 68Ga-DOTA-TOC – SUV with IRS of
SSTR2A
– SUV with tumor-
absorbed doses
after PRRT
Idem – Limited to SSTR2 and
SSTR5 expression
– Tumor dedifferentiation
and loss of SSTR
expression
SSTR2, SSTR3,
SSTR5
68Ga-DOTA-NOC – SUV with IRS of
SSTR2A and SSTR5
Idem
– Superior to other
68Ga-radiolabeled peptides
– Tumor dedifferentiation
and loss of SSTR
expression
Catecholamine
transporter and
synthesis
18F-DOPA – Urinary levels of
5-HIAA
– No correlation with
SSTR
–Whole-body scan possible
– Greater sensitivity than SRS
– Role in negative SRPET and
inconclusive conventional
imaging
– Greater sensitivity in
functioning tumors
– Lower sensitivity than
68Ga-labeled PET
Catecholamine
transporter and
synthesis
11C-5-HTP – Urinary levels of
5-HIAA
– Same as 18F-DOPA – Very short half-life of
radiotracer
– Very low availability
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anatomical and functional or molecular imaging techniques,
including diffusion-weighted imaging (DWI), dynamic
contrast-enhanced MRI (DCE-MRI), and magnetic resonance
spectroscopic imaging (MRSI). NETs are typically best ob-
served in fat-suppressed T1-weighted sequences, such as low
signal intensity lesions, and typically become hyperintense on
T2-weighted sequences. Intravenous contrast enhancement is
also essential for adequate characterization. Improved lesion
detection and characterization have been documented with
MRI for certain anatomic locations, such as the liver or pan-
creas. MRI is the best conventional imaging technique to de-
tect hepatic metastases in GEP-NETs (sensitivity of 95%) and
shows a good performance for the detection of primary
pancreatic NETs (sensitivity 74–94 %, specificity 78–
100 %), although it is less useful than CT for the detection
of primary small bowel lesions [15, 16]. However, MRI is still
more expensive and time-consuming than CT and requires
greater patient cooperation. These factors limit the widespread
use of MRI, which is generally used as a problem-solving tool
in patients with negative or equivocal findings resulting from
other diagnostic procedures [9–11].
Transabdominal US is an inexpensive technique that may be
used to screen solid organs in the abdomen or to direct needle
biopsy for histological diagnosis (spatial resolution 50–
100 μm). GEP-NETs are typically visualized as hypoechoic,
well-defined masses commonly surrounded by a hyperechoic
halo. The sensitivity of US for detecting GEP-NETs is, never-
theless, limited, ranging from 15 to 80 % depending on tumor
size and anatomical localization [5, 9–11]. Its utility is further
limited in patients with abundant abdominal gas or in very
large/fat patients, as sound waves are attenuated as they pass
deeper into the body. Improved image resolution can be
achieved using a high-frequency endoscopic US (EUS) probe
(7.5–12 MHz) that enables the transducer to maintain close
proximity to target lesions. The sensitivity of this probe is sub-
stantially higher than the standard US probe (3–5 MHz) and is
especially helpful for detecting small lesions in the pancreatic
head or duodenal wall [17]. In fact, EUS sensitivity is higher
than that of the CT scan in this context (92 vs. 63 %), particu-
larly for detecting small insulinomas (84 vs. 32%) [18]. EUS is,
nonetheless, invasive, technically difficult, operator-dependent,
and not widely available [5, 9–11]. Finally, intraoperative US
(IOUS) may be an important aid in the surgical exploration of
the pancreas and liver.
Finally, multimodal imaging is able to provide a combina-
tion of anatomical, molecular, and functional imaging quanti-
tative parameters of tumor phenotype. In modern scanners,
positron emission tomography (PET) and single photon emis-
sion computed tomography (SPECT) are combined with an
anatomical cross-sectional counterpart such as CT (PET/CT
and SPECT/CT) and also MRI (PET/MRI) [19]. These hybrid
techniques have demonstrated to be useful of GEP-NETs for
tumor detection, staging, and tumor response evaluation [20].
Table 1 (continued)
Imaging
modality
Principle/target Mechanism/radiotracer Biological correlation Advantages Limitations
– No correlation with
SSTR
Glucose transporter 18F-FDG – Ki-67 % –Whole-body scan possible
– Poorly differentiated and/or
highly proliferative tumors
– Useless in well-
differentiated tumors
CT computed tomography, DCE dynamic contrast-enhanced, 5-HIAA 5-hydroxyindoleacetic acid, IRS immunoreactive score of Remmele and Stegner,
MRImagnetic resonance imaging,PET/CT positron emission tomography/computed tomography, SPECTsingle photon computed tomography, SPECT/
CT single photon tomography/computed tomography, SSTR somatostatin receptors, SUV standard uptake value in PET/CT images, US ultrasound
Fig. 1 Coronal reformatted arterial phase contrast-enhanced
multidetector CT image demonstrates multiple enteropancreatic
neuroendocrine tumors (arrows) in a patient with MEN-1. These
tumors and their metastases are often hypervascular. They are usually
more conspicuous in the early arterial acquisition phase
826 Cancer Metastasis Rev (2015) 34:823–842
2.2 Standard size-based evaluation criteria
The first widely adopted criteria for evaluating cancer thera-
pies were developed by the World Health Organization
(WHO) in 1979 and were primarily intended for use in clinical
trials that had a tumor response as the primary endpoint [21].
The WHO criteria were the first set of rules to introduce the
concept of overall assessment of tumor burden based on the
sum of the bidimensional products of tumor lesions. In addi-
tion, they defined the response to therapy based on the
percentual change from baseline. This standardization facili-
tated a common universal language for reporting the results of
cancer therapy in a consistent manner to enable cross-trial
comparisons. Numerous modifications of the WHO criteria
were subsequently made to clarify uncertain issues in the orig-
inal document and to accommodate emerging new technolo-
gies such as CT and MRI. These revisions led, paradoxically,
to the response criteria being no longer comparable among
research organizations. An International Working Party was
thereby constituted to simplify and standardize again the eval-
uation criteria that resulted in the Response Evaluation
Criteria In Solid Tumors (RECIST, version 1.0) [3]. Key fea-
tures of these updated criteria included the use of one-
dimensional measurements for assessing tumor burden, the
definition of the minimum size of measurable lesions to be
selected as targets, instructions on howmany lesions to follow
and how, and a model for the overall response assessment
combining both target and nontarget lesions [3, 4]. In addition,
time to progression and PFS, which can be assessed in all
patients, as opposed to duration of response that can only be
quantified in responders, were briefly discussed as alternative
endpoints in certain circumstances (i.e., investigation of
noncytoreductive anticancer agents) [7, 8].
An updated version of RECIST (version 1.1) was published
in 2009 [4] to address several questions and pending issues,
including how to apply RECIST in trials in which progression,
rather than response, is the primary endpoint, or in trials of
targeted noncytotoxic drugs. Whether and how to use newer
imaging technologies, such as 18F-fluorodeoxyglucose positron
emission tomography (18F-FDG-PET) and MRI, was also ad-
dressed. A summary of the evolution from WHO response
criteria to RECIST 1.1 is presented in Table 2.
2.3 Pitfalls of size-based response assessment
in GEP-NETs
The RECIST criteria have been widely adopted by academic
institutions, cooperative groups, and industry as a standard
method for reporting clinical trials. The primary strengths of
these criteria are simplicity, reproducibility, and universal ac-
ceptance, which allow outcomes across different trials to be
compared. Nevertheless, a number of limitations remain, and
several unique features of tumor biology and specific cancer
therapies make their applicability particularly challenging in
the field of GEP-NETs [22, 23].
RECIST dichotomize patients into responders versus non-
responders to quantify drug efficacy, the latter category in-
cluding both stabilization of disease (which in certain scenar-
ios may be actually indicative of a drug-induced antiprolifer-
ative effect) and disease progression. Even the latest version of
RECIST primarily focuses on the use of objective response
endpoints for phase II trials [24]. In the context of GEP-NETs,
however, this may be only applicable to poorly differentiated,
highly proliferative tumors that are treated with cytotoxic ther-
apy. As the majority of GEP-NETs are well-differentiated,
slow-growing tumors, and novel targeted agents are increas-
ingly being used to treat this disease, alternative definitions of
tumor response are being actively explored and greater em-
phasis is being placed on progression-based endpoints [23].
Other means for assessing treatment effects, such as a mi-
nor response (tumor shrinkage <30%), disease control rates (a
combination of objective response and stable disease), or the
proportion of patients that are progression-free at landmark
time points, could be considered as alternative metrics for
providing early indications of an agent deserving additional
clinical development. A major limitation to this approach in
the field of GEP-NETs is to accurately estimate the expected
disease stabilization rate, in the absence of a treatment effect,
in this generally indolent disease. For this reason, a random-
ized controlled design is preferred, when feasible, for phase II
screening trials in this context.
Several recent studies have illustrated how alternative met-
rics may more accurately reflect the therapeutic effect of med-
ications in well-differentiated GEP-NETS. Indeed, two so-
matostatin analogs (octreotide and lanreotide) and two
targeted agents (everolimus and sunitinib) significantly im-
prove PFS of patients with different subtypes of GEP-NETs
with little or no effect on tumor volume (objective response
rate <10 % by RECIST) [5–8]. Waterfall plots of pivotal ran-
domized trials, such as RADIANT-3 to evaluate everolimus in
pancreatic NETs, showed that the proportion of patients
achieving any degree of tumor shrinkage was substantially
greater in everolimus-treated patients (64 %) than in patients
in the placebo control arm (21 %), although response rates
were low in both treatment arms (5 vs. 2 %) [8]. The current
thresholds used to define tumor progression (≥20 %), which
have become more conservative over time, have also been
questioned in the context of slow-growing GEP-NETs. How-
ever, caution should be advised in lowering this threshold, as
validation would be required to ensure that the measurement
errors are actually inferior to the cutoff values, and this is not
an easy task due to the technical difficulties frequently en-
countered in the precise definition of lesions in NETs.
Other clinical settings that question the validity of RECIST
to address treatment failure include clinical or biochemical
progression in the absence of radiological progression, focal
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progression that is amenable to local therapy (e.g., small bow-
el obstruction with stable liver metastasis), or indolent asymp-
tomatic progression. Some technical difficulties inherent to
identifying and monitoring metastases in certain patients with
GEP-NETs may also limit the application of RECIST. These
include patients with small volume metastatic disease or, con-
versely, extensive liver involvement with either multiple small
or large confluent liver metastases, which can form conglom-
erate masses that may be difficult to individualize and moni-
tor. In addition, certain targeted agents (e.g., angiogenesis in-
hibitors) may induce necrosis or cystic changes in the tumor
that are not only not associated with tumor shrinkage but may
even render preexisting lesions more visible, which may be
misleading and erroneously interpreted as progressive disease
rather than as a positive therapeutic effect. Finally, residual
masses may not be adequately differentiated from fibrosis,
with no viable tumor, by means of standard imaging modali-
ties, and would never be considered as complete responses by
RECIST [23].
2.4 Alternative response evaluation criteria
Beyond size, additional radiological parameters can also pro-
vide very valuable information in terms of antitumor efficacy
and are increasingly being considered when evaluating re-
sponse in certain tumor types treated with specific targeted
agents. Indeed, necrosis, hemorrhage, and myxoid degenera-
tion may reflect pathologic tumor response in the absence of
significant tumor shrinkage. One of the most representative
examples of this effect was soon documented in gastrointesti-
nal stromal tumors (GIST) after the introduction of imatinib.
The dramatic changes in tumor density induced by this drug,
as determined by measuring CT attenuation coefficient in
Hounsfield units (HU), led Choi to propose in 2007 a new
set of criteria that combined changes in both size and density
for tumor response assessment in this setting [25] (Table 3).
These criteria and their variants are nowwidely applied in GIST
and are being prospectively evaluated in other neoplastic dis-
eases. Preliminary data in patients with pancreatic NETs
Table 2 Evolution of tumor response criteria: from WHO to RECIST 1.1
WHO RECIST 1.0 RECIST 1.1
Method to assess
tumor burden
Sum of products of the longest
and greatest perpendicular
diameters of all measured
lesions (bidimensional)
Sum of longest diameters of target
lesions (one-dimensional)
Sum of longest diameters for nonnodal
and short axis for nodal target lesions
(one-dimensional)
Definition of
measurable disease
Not specified CT: ≥10 mm with spiral CT
≥20 mm with nonspiral CT
Clinical: ≥20 mm
LN, not specified
CT: ≥10 mm longest diameter for nonnodal
≥15 mm short axis for nodal lesions
Clinical: ≥10 mm (measured with calipers)
Special considerations for bone and cystic
lesions
Number of target
lesions to follow
Not specified Maximum of 10 lesions
(up to 5 per organ)
Should be those with longest
diameters, representative of all
involved organs, and most
suitable for accurate repeated
measurement
Maximum of 5 lesions (up to 2 per organ)
Should be those with longest diameters,
representative of all involved organs, and
most suitable for accurate repeated
measurement
Response categories
• CR Disappearance of all known
disease, confirmed at
4 weeks
Disappearance of all known
disease, confirmed at 4 weeks
Disappearance of all target and nontarget
lesions
LN <10 mm short axis
• PR ≥50 % decrease of tumor
burden, in the absence of
new lesions, confirmed at
4 weeks
≥30 % decrease of tumor burden,
taking baseline sum as reference,
in the absence of new lesions,
confirmed at 4 weeks
≥30 % decrease in tumor burden, taking
baseline sum as reference, in the absence
of new lesions, to be confirmed at 4 weeks
only in nonrandomized trials with response
as primary endpoint
• SD Neither sufficient shrinkage to
qualify for PR nor sufficient
increase to qualify for PD
Neither sufficient shrinkage to
qualify for PR nor sufficient
increase to qualify for PD
Neither sufficient shrinkage to qualify for
PR nor sufficient increase to qualify for PD
• PD ≥25 % increase in tumor
burden or appearance of
new lesions
≥20 % increase in tumor burden,
taking the smallest sum since
treatment started as reference,
or appearance of new lesions
≥20 % increase in tumor burden, taking the
smallest sum since treatment started as
reference, with a minimum absolute value
increase ≥5 mm or appearance of new
lesions
CR complete response, LN lymph nodes, PD progressive disease, RECISTResponse Evaluation Criteria In Solid Tumors, PR partial response, SD stable
disease, WHO World Health Organization
828 Cancer Metastasis Rev (2015) 34:823–842
suggest that Choi criteriamay help to early discriminate patients
who might benefit from sunitinib or everolimus therapy [26].
Other alternative methods to evaluate tumor response
(Table 3) have been described in detail elsewhere [27–30]
and are beyond the scope of this review. Briefly, these
methods take into consideration additional parameters such
as arterial enhancement (e.g., the European Association for
Study of the Liver (EASL) criteria in hepatocellular carcino-
ma) [27], treatment-induced tumor necrosis, or other structural
changes (e.g., the Morphology, Attenuation, Size and Struc-
ture (MASS) criteria for renal cancer treated with
antiangiogenic agents, or the Lee criteria for nonsmall cell
lung cancer treated with EGFR inhibitors) [31, 32]. Specific
criteria have also been developed for novel therapeutic strate-
gies (e.g., immune-related response criteria) [33] or imaging
modalities such as PET (e.g., PET response criteria in solid
tumors or PERCIST) [30, 34, 35].
18FDG-PET assesses tumor glucose uptake, which broadly
correlates with cancer cell viability. 18FDG uptake may
therefore provide an early and sensitive pharmacodynamic
marker for monitoring response to antiproliferative agents
[36]. Changes in 18FDG uptake measured by PET have been
correlated with a pathological tumor response and overall sur-
vival in certain neoplastic diseases. Caution should be ad-
vised, nevertheless, as 18FDG-PET is a sensitive but nonspe-
cific method for detecting malignancy sites. Areas of active
inflammation or infection are common sources of false-
positive findings [37]. A period of at least 10 days (or prefer-
ably up to 3 weeks) is advised before a PET scan is performed
following chemotherapy administration, to bypass transient
fluctuations of 18FDG uptake, either stunning or flare of tumor
uptake, which may occur soon after treatment. False-negative
findings may also arise when evaluating small lesions. PET
imaging is progressively being incorporated for staging and
response assessment in a number of malignancies (e.g., lym-
phoma) [38]. In the context of GEP-NETs, however, it would
be only applicable to highly proliferative or poorly differenti-
ated tumors, as guidelines have been specifically developed
Table 3 Alternative functional tumor response criteria
Response
categories
Response criteria
Choi mRECIST MASS PERCIST
CR Disappearance of all lesions
and no new lesions
Disappearance of any
intratumor arterial
enhancement in all target
lesions
No new lesions
Favorable response
≥20 % decrease in tumor burden
per RECIST or
≥10 % decrease in tumor burden
per RECIST and≥half of
nonlung target lesions with
a ≥20 HU decreased mean
attenuation or
One or more nonlung target
lesions with a ≥40 HU
decreased mean attenuation
No new lesions
Complete resolution of 18F-FDG
uptake within tumor volume so
that it is less than mean liver
activity and indistinguishable
from surrounding
background blood-pool levels
PR ≥10 % decrease in tumor
burden per RECIST or
≥15 % decrease in tumor
density (HU) on CT scan
and no new lesions nor
unequivocal progression
of nonmeasurable disease
≥30 % decrease in tumor
burden per RECIST
considering only viable
tumor of target lesions
(that with arterial
enhancement on CE
radiological techniques)
No new lesions
≥30 % relative and ≥0.8 absolute
decrease in 18F-FDG uptake
(SUL peak of target lesion) and
no >30 % increase in SUL of
nontarget lesions and no PD by
RECIST
ROI does not need to be in precise
same area as baseline scan
SD Does not meet criteria for
complete, partial, nor
progressive disease and
No clinical deterioration
attributable to tumor
progression
<30 % decrease to ≤20 %
increase in the sum of
maximum arterial enhancing
diameter of target lesions
No new lesions
Indeterminate response
Does not fulfill criteria for
favorable or unfavorable
response
No new lesions
Does not fulfill criteria for partial
response nor for progressive
disease
PD ≥10 % increase in tumor size
per RECIST that does not
meet criteria for PR by
tumor density on CT scan or
Appearance of new lesions
including new intratumor
nodules or increase in size
of existing nodules
>20 % increase in tumor
burden per RECIST
considering only viable
tumor of target lesions or
Appearance of new lesions
Unfavorable response
≥20 % increase in tumor burden
per RECIST or
Target lesion with central necrosis
changing to near complete
enhanced solid tumor or
New enhancement in a
nonenhancing lesion or
Appearance of new lesions
>30 % relative and 0.8 absolute
increase in 18F-FDG uptake
(SUL peak of target lesion) or
Unequivocal increase in extent of
18F-FDG uptake (75 % in total
lesion glycolysis volume with
no decline in SUL) or
New 18F-FDG-avid lesions
18 F-FDG 18 F-fluorodeoxyglucose, CT computed tomography, EASL European Association for Study of the Liver, EORTC European Organization for
Research and Treatment of Cancer, HU Hounsfield unit, MASS morphology, attenuation, size and structure, mRECIST modified RECIST, PERCIST
Positron Emission Response Criteria In Solid Tumors, PET positron emission tomography, RECIST Response Evaluation Criteria In Solid Tumors, ROI
region of interest, SUL standard uptake value
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for the 18FDG radionuclide. Whether these criteria may be
applied to other radiotracers (e.g., 68Gadolinium-
tetraazacyclododecane tetraacetic acid (68Ga-DOTA) pep-
tides) remains to be elucidated. Nevertheless, prospective tri-
als for validating these response criteria are warranted.
3 New imaging modalities for assessing GEP-NETs
3.1 Cancer-specific functional imaging
Functional imaging refers to the visualization, characteriza-
tion, and quantification of biological processes at the cellular
or molecular level. The unique features of GEP-NETs provide
distinct targets for cancer-specific functional imaging, such as
somatostatin receptors (SSTR), or catecholamine transporter
and synthesis pathways. Consequently, an increasing number
of radiopharmaceuticals are becoming available to detect and
quantify different aspects of the heterogeneous biology of
GEP-NETs (Table 1). Several techniques that are increasingly
being used in clinical practice will be discussed below.
3.1.1 Somatostatin receptor imaging: SRS and 68Ga-DOTA
peptides
Scintigraphy with radiolabeled somatostatin analogs (SRS) is
a very useful imaging technique for detecting tumors express-
ing somatostatin receptors. 111In-DTPA-D-Phe1-octreotide
(111In-pentetreotide), a metabolically stable radiopharmaceu-
tical with a high affinity for type 2 somatostatin receptors
(SSTR2), is the most commonly used tracer for imaging
GEP-NETs [39–41]. The major limitations of SRS are the
evaluation of organs with higher physiological uptake (e.g.,
liver and gut) and the detection of small lesions owing to its
low spatial resolution (range 7–15 mm) [42]. The addition of
SPECT to SRS planar views and, more recently, the multi-
modal devices that combine SPECT and computed tomogra-
phy (SPECT/CT) have led to improved tumor detection.
These approaches enable a more precise identification of the
physiological uptake of the radiolabeled analog and a better
definition of the functional significance of lesions detected by
CT (Fig. 2) [43, 44].
Next-generation somatostatin analogs have been devel-
o p e d u s i n g t h e c h e l a t o r DOTA r a t h e r t h a n
diethylenetriaminepentacetate (DTPA), and these molecules
can also be labeled using positron-emitting radionuclides,
such as 68Ga (Table 1). 68Ga-DOTA-Tyr3-octreotide (68Ga-
DOTA-TOC), 68Ga-DOTA-Tyr3-octreotate (68Ga-DOTA-
TATE), and 68Ga-DOTA-1-NaI3-octreotide (68Ga-DOTA-
NOC) [45] add higher SSTR affinity and more favorable phar-
macokinetic properties (namely, more rapid extraction and
clearance) to the improved spatial resolution of PET relative
to SRS (range 4–10 mm). 68Ga-labeled somatostatin receptor
PET (SRPET) is in fact increasingly being used in specialized
centers and will replace SRS in the near future. Indeed, a
recent meta-analysis has shown that SRPET has a higher
Fig. 2 SRS using 111In-
pentetreotide (a) and 18F-FDOPA
PET/CT (b) performed 1 week
apart in a patient with a well-
differentiated metastatic ileal
NET. Planar scintigraphy (a1)
shows an uncertain liver lesion
(red arrow), clearly located in
segment II of the liver in the
SPECT/CT fusion image (a2).
Whole-body PET/CT image
using 18F-FDOPA (b1 and b2)
shows the same liver metastasis
(red arrow) but also detects an
additional liver lesion in segment
V (yellow arrow). Follow-up 18F-
FDOPA PET/CT (c1 and c2)
performed after 12 cycles of
octreotide therapy identifies
multiple hepatic and peritoneal
implants (both abdominal and
subdiaphragmatic costophrenic
angle) reflecting tumor
progression
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diagnostic accuracy (sensitivity, 93 %; specificity, 96 %) than
that reported for SRS (sensitivity, 82–95 %; specificity, 50–
80%) [46]. Additional advantages of SRPET include the short
scanning time required, the relatively low radiation exposure,
and the availability of 68Ga generators.
Sensitivity may substantially vary depending on the tumor
type and the specific binding and affinity profile of the
radiopeptide used [47]. SSTR2A and SSTR5 are the most
frequently expressed SSTRs in GEP-NETs (86 and 62 %, re-
spectively), followed by SSTR1 [48–50]. Nevertheless,
SSTR2A expression varies significantly among different
GEP-NETs and is much less frequent in insulinomas (58 %)
than in gastrinomas (100 %) or carcinoid tumors (86 %).
Overall, well-differentiated neoplasms have a higher density
and more homogeneous distribution of SSTRs than poorly
differentiated endocrine carcinomas, except for SSTR5 that
shows the opposite trend. SSTR expression is generally lower
in pancreatic than in gastrointestinal tumors except SSTR3,
which has greater expression in pancreatic than in enteric
NETs (40 vs. 21 %). On the other hand, SRS using 111In-
pentetreotide has high affinity for SSTR2, and consistently,
comparative analyses have revealed a high correlation be-
tween tumor detection using SRS and SSTR2A expression
assessed by immunohistochemistry (Table 2). However,
68Ga-labeled DOTA peptides show superior affinity for
SSTR2 than 111In-pentetreotide. 68Ga-DOTA-TATE has the
highest affinity for SSTR2, but only 68Ga-DOTA-NOC shows
high affinity for SSTR3 and SSTR5 (Table 4). Concordant
with these affinity profiles, tissue immunoreactive scores for
SSTR2A and SSTR5 correlate with SUV values on PET/CT
using 68Ga-DOTA-NOC [50], and SSTR2A correlates with
68Ga-DOTA-TOC [51]. Such differences should be consid-
ered in the clinical setting because sensitivity may be lower
with 111In-pentetreotide SRS or 68Ga-DOTA-TATE SRPET
for certain tumor types, such as insulinomas, whereas 68Ga-
DOTA-NOC may be more suitable for pancreatic NETs [49].
The clinical applications of these new imaging modalities
are likely to expand because novel somatostatin analogs are
being developed with increased affinity for different SSTR
subtypes. For example, whereas octreotide and lanreotide
have high affinity for SSTR2, pasireotide, a new somatostatin
analog not approved for the treatment of NETs, has a higher
affinity for the remaining SSTRs, especially SSTR5. In this
context, future studies should address the potential correlation
between specific SSTR tumor expression profiles assessed by
immunohistochemistry and molecular imaging and response
to SSTR-targeted therapy [50] (Fig. 3). Nevertheless, poorly
differentiated GEP-NETs are more suited to be characterized
using the most widely available radiotracer (18F-FDG), which
reflects the increased glucose transport of rapidly proliferating
cells. Indeed, the sensitivity of 18F-FDG PET for depicting
GEP-NETs with high proliferative indices (Ki-67 >15 %) ex-
ceeds that of SRS (92 vs. 69%), and 18F-FDG SUVuptake is a
stronger prognostic factor in this context than traditional bio-
chemical or histological markers, such as chromogranin A
(CgA) or Ki-67 index [40, 41].
Procedure guidelines for SRS and SRPET tumor imaging
by the European Association of Nuclear Medicine (EANM)
and European Neuroendocrine Tumors Society (ENETS)
have included monitoring of response to different therapies
in their clinical indications [42, 52, 53]. With the emergence
of PRRT as a novel treatment strategy for GEP-NETs, molec-
ular imaging has gained relevance as a potential tool for ther-
apy response assessment. SSTR tumor expression document-
ed by SRS and, more recently, SRPET is a prerequisite for
PRRT planning in GEP-NETs [54]. Initial reports failed to
show an additional advantage of 68Ga-DOTA-TOC PET/CT
over conventional radiologic imaging (CT or MRI) in evalu-
ating response to PRRT, except for an earlier detection of
metastatic disease in a subgroup of patients using SRPET
[55]. In contrast, a transient decrease in 68Ga-DOTA-TATE
tumor uptake after the first cycle of PRRT was predictive of
time to progression and symptom relief in patients with GEP-
NETs, withΔSUVT/S (tumor/spleen SUV ratio) being superi-
or to ΔSUVmax for prediction of outcome [56]. Notably, the
lack of SSTR expression assessed by 68Ga-labeled PET imag-
ing and the documentation of hypermetabolism by 18F-FDG
PET have been associated with rapid progression and poor
prognosis in GEP-NET patients treated with both PRRT and
watchful waiting follow-up strategies, suggesting that these
molecular imaging techniques also characterize tumor biology
independently of therapy [57, 58].
Table 4 Radiopeptide affinity
(IC-50 values in nmol/L) profile
for somatostatin receptors (SSTR)
commonly expressed in NETs
SSTR2A (nmol/L) SSTR3 (nmol/L) SSTR4 (nmol/L) SSTR5 (nmol/L)
SRS
111In-pentetreotide 22 – – –
SRPET
68Ga-DOTA-TOC 2.5 – – 73
68Ga-DOTA-TATE 0.2 – – –
68Ga-DOTA-NOC 1.9 40 – 7.2
SSTR somatostatin receptor, SRS somatostatin receptor scintigraphy, SRPET somatostatin receptor positron emis-
sion tomography, − low or absence of affinity
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More recent reports have correlated baseline (pretherapeutic)
68Ga-PET SUV values with the subsequent absorbed dose of
radiopharmaceuticals and the clinical outcome after PRRT, both
with 177Lu-DOTA-TATE and 90Y-DOTA-TOC. Moreover, the
mean per-cycle decrease of tumor-absorbed dose was linked to
the morphologic response following treatment with 177Lu-
DOTA-TATE, suggesting that sequential changes of tumor-
absorbed doses could be appropriate early markers of therapeu-
tic response. These observations reinforce the potential role of
SRPET for the prediction of outcome after PRRT, providing the
rationale for individual dosing and allowing a more appropriate
selection of patients who might benefit from this therapeutic
strategy [59–62]. Additional larger and prospective studies
should be performed, nonetheless, to ascertain these correla-
tions and to standardize and validate appropriate cutoff values
of quantitative molecular parameters before these techniques
can be widely used for clinical decision-making. The possibility
of tumor dedifferentiation with loss of SSTRs should also be
considered as an additional limitation to SRPET, although it
may be overcome by using different radiotracers (e.g., 18F-
FDG). Finally, molecular imaging could also have a role in
evaluating response to treatment modalities other than PRRT,
including cytotoxic agents or Bcold^ targeted agents; however,
this has not been formally assessed to date.
In summary, the lack of spatial resolution and detectability
of conventional SRS has been partially overcome using mul-
timodal tomographic techniques (SPECT/CT). However, the
advent of new devices with higher spatial resolution such as
PET/CT or even PET/MRI using new generation radiotracers
provides the highest available sensitivity (detection of radio-
tracer concentration in tissue at the nanomolar range). These
advantages might therefore compensate some of the
limitations that traditionally have been ascribed to nuclear
medicine techniques. Standardization and validation of these
novel techniques and assessment criteria in prospective clini-
cal trials, to ensure results are reliable and reproducible, are
essential however before their widespread use in everyday
clinical practice.
3.1.2 Catecholamine transporter and synthesis: 18F-DOPA
and 11C-5-HTP
Alternative molecular imaging techniques exploit the intrinsic
property of neuroendocrine cells for amine precursor uptake
and decarboxylation (the APUD system). Several precursors,
such as 5-hydroxy-L-tryptophan (5-HTP) and L-
dihydroxyphenylalanine (L-DOPA), are taken up by neuroen-
docrine cells and converted to serotonin and dopamine, re-
spectively. These precursors can be labeled to produce PET
tracers that are useful for GEP-NET imaging. Themost widely
available marker is 18F-fluoro-L-3,4-dihydroxyphenylalanine
(18F-DOPA), which enters the neuroendocrine cells via an L-
type amino acid sodium-independent transporter (LAT).
There, it is subsequently decarboxylated by the aromatic L-
amino acid decarboxylase, an enzyme highly expressed in
neuroendocrine cells, resulting in 18F-dopamine. Then, this
molecule is transported into cytoplasmic storage secretory
vesicles and protected from enzymatic degradation, thereby
promoting its intracellular retention. A high 18F-DOPA uptake
is commonly observed in neuroendocrine tumor cells, partic-
ularly in small-bowel serotonin-producing NETs [63].
18F-DOPA has greater sensitivity for GEP-NET detection
than SRS (Fig. 2), even when SPECT/CT is used [64]; how-
ever, comparative studies between 18F-DOPA and 68Ga-
Fig. 3 SRPET using 68Ga-
DOTANOC in a patient with
multiple liver metastases of a
well-differentiated ileal NET.
PET/CT scans performed before
(left) and after 4 cycles of PRRT
(177Lu-DOTA-TATE) and
subcutaneous monthly lanreotide
(right) show a partial response to
therapy (courtesy of Valentina
Ambrosini and Stefano Fanti, S.
Orsola-Malpighi University
Hospital, Bologna, Italy)
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DOTA peptides tilt the balance in favor of SRPET in terms of
diagnostic accuracy [65]. In this regard, it is important to note
the lack of correlation between 18F-DOPA transport and de-
carboxylation and the expression of SSTR depicted by
SRPET [66]. Thus, 18F-DOPA PET/CT is generally recom-
mended for GEP-NET diagnosis when conventional radiolog-
ical imaging and SRS or even SRPET show negative or in-
conclusive findings.
18F-DOPA PET, as a molecular imaging tool that reflects
cellular metabolic activity rather than receptor density, has
been postulated to be likely a more appropriate tool to monitor
treatment response. Supporting this hypothesis, 18F-DOPA
uptake is frequently increased in GEP-NET patients with ele-
vated plasma serotonin, and whole-body metabolic tumor bur-
den (WBMTB) assessed using 18F-DOPA PET is correlated
with urinary and plasma levels of tumor markers belonging to
the serotonin and catecholamine pathways [66, 67]. Interest-
ingly, urinary excretion of 5-hydroxyindoleacetic acid (5-
HIAA), the primary metabolite of serotonin, is also a reliable
indicator of tumor burden and metabolic activity and one of
the most widely used markers for response assessment and
follow-up of patients with functioning GEP-NETs. WBMTB
could therefore potentially become an alternative parameter
for evaluating disease extent, biochemical activity, and tumor
response in these patients.
The 11C-5-hydroxy-L-tryptophan (11C-5-HTP) PET tracer,
a precursor of serotonin, is a useful universal imaging tool for
detecting GEP-NETs, with greater sensitivity than CTor SRS.
11C-5-HTP PET seems to perform better than 18F-DOPA for
the overall detection of GEP-NETs; but unlike 18F-DOPA, its
use is restricted to a few specialized centers as the 11C radio-
isotope has a very short half-life. This radiopharmaceutical is
generally used, if available, when conventional imaging pro-
cedures fail to locate an occult tumor, or for follow-up pur-
poses when clinical, biochemical, and standard radiological
assessments are equivocal or show conflicting results [68].
A close correlation between changes in 11C-5-HTP transport
rate and urinary 5-HIAA excretion during medical treatment
indicates its potential as a means for monitoring treatment
efficacy [69]. However, besides anecdotal case reports, studies
assessing the value of serial changes in 18F-DOPA or 11C-5-
HTP PET metabolic parameters for evaluating response to
therapy are still lacking.
Other NET-specific radiolabeled peptides, currently in pre-
clinical or early clinical development, include glucagon-like
peptide-1 (GLP-1), cholecystokinin (CCK), gastrin, bombesin,
substance P, vasoactive intestinal peptide (VIP), and neuropep-
tide (NP)-Y analogs. Additional noncancer-specific tracers of
potential use in GEP-NETs include 18F-fluoro-L-thymidine
(18FLT)-PET, a nonspecific marker of proliferation, and 18F-
fluoro-misonidazole (18FMISO)-PET, which accumulates in
hypoxic tissues and could hence be a potential biomarker for
assessing response to antiangiogenic therapy.
3.2 Therapy-specific functional imaging
As treatment options for GEP-NETs continue to expand, eval-
uation of therapeutic response solely on the basis of size clear-
ly has substantial limitations, particularly in the era of targeted
therapy. Indeed, new therapeutic modalities, such as angio-
genesis inhibitors, may significantly increase patients’ surviv-
al by inducing a cytostatic effect that does not necessarily
translate into tumor shrinkage (e.g., tumor necrosis or cavita-
tion with no size reduction). Functional imaging techniques
that monitor specific physiological and cellular processes
within the tumors in response to antineoplastic agents with
novel mechanisms of action are therefore gaining momentum
[22, 70–74]. In fact, these alternative response assessment
techniques are increasingly being implemented at earlier
stages of drug development. The main features of these imag-
ing modalities are summarized in Table 1.
DCE imaging methods may be applied to US, CT, or MRI
with contrast dyes specific to each modality. These imaging
techniques assess tumors based on the appreciable differences
between the heterogeneous, chaotic, and leaky neoplastic vas-
cular network and the normal physiological vasculature of
healthy tissues [22, 74]. A rapid sequence of images is ac-
quired through a volume of interest before, during, and after
the intravenous administration of contrast material. These data
are then fitted to mathematical models to analyze a number of
physiological processes and to obtain quantitative perfusion
parameters that reflect the vascular characteristics of the ex-
amined tissue, including blood volume (BV), blood flow
(BF), mean transit time, and permeability area. Although ex-
perience is limited, DCE-US, DCE-CT, and DCE-MRI are
likely to become useful tools for characterizing GEP-NETs
[75, 76] and to evaluate their biologic aggressiveness [77],
therapeutic response [22, 74] (Fig. 4), and prognosis [78, 79].
DCE-US enables the quantification of perfusion parame-
ters by injecting ultrasonic microbubble-based contrast dye,
and international guidelines have been produced to standard-
ize this technique [80]. Among these parameters, the area
under the perfusion curve (AUC)—a criterion linked to
BV—has been identified as a reliable early predictor of re-
sponse to antiangiogenic therapy using the RECIST criteria
[81]. This finding was further validated in a multi-institutional
cohort of 539 patients with various tumor types, including
GEP-NETs, treated with different antiangiogenic agents
[82]. In this group, early decreases in perfusion parameters
were significantly associated with improved time to disease
progression and overall survival. DCE-US has also been test-
ed in a small study of patients with GEP-NETs who were
treated with transarterial embolization (n= 10) or
chemoembolization (n=7). The authors proposed a new com-
posite parameter combining functional and morphological da-
ta, named tumor vitality index, which may warrant additional
exploration [83]. DCE-US allows early identification of tumor
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structural changes in response to PRRT, as decreased perfu-
sion parameters are documented as soon as 6 weeks after
therapy, whereas morphological changes may require a mini-
mum of 6 months follow-up to be detectable [84]. DCE-US
yielded comparable results to DCE-CT in the assessment of
perfusion and morphological changes of liver metastases, par-
ticularly lesions located in the caudal and ventral parts of the
liver, although adequate visualization of subdiaphragmatic
structures remains an important limitation of this technique.
DCE-CT, also called perfusion CT, similarly enables the
quantification of perfusion parameters to characterize tumor
vascular features without some of the limitations of DCE-US
(Fig. 4). The main drawbacks of this approach are the lack of
standardization for data interpretation and the high radiation
dose required. A significant correlation between tumor BF
assessed by DCE-CT and histological assessment of
intratumormicrovessel density has been reported in pancreatic
NETs [78]. Of note, a higher BF was observed in tumors with
lower proliferation indexes, less aggressive histological fea-
tures, and improved prognosis, as opposed to what may be
found in other malignancies [78, 85]. DCE-CT has success-
fully been used to assess tumor perfusion changes in response
to therapy in a small randomized phase II study comparing
two antiangiogenic therapies, bevacizumab versus pegylated-
interferon alpha 2b, in patients with advanced carcinoid tu-
mors [86, 87]. A significant decrease in BF and BV was early
observed (day 2 perfusion CT) compared with baseline data in
bevacizumab-treated patients, but not in patients treated with
interferon. Decrease in tumor BF following bevacizumab
therapy was proportional to baseline BF suggesting
bevacizumab decreased BF by a fixed percentage.
Bevacizumab also induced objective responses by RECIST
(18 vs. 0 % in bevacizumab vs. interferon arm) and was asso-
ciated with longer PFS than the control arm. A subsequent
study by the same group randomized 39 patients with low-
to intermediate-grade NETs to receive bevacizumab or evero-
limus for one 21-day cycle, adding the alternate agent on cycle
2 (bevacizumab + everolimus). Serial functional CT assess-
ments were mandatory. Bevacizumab significantly decreased
tumor BF (44%, p<0.0001), and the addition of everolimus to
bevacizumab was associated with further decrease in BF
(29 %, p=0.02). Everolimus alone was associated with 13 %
increase in mean transit time (p=0.02). Notably, several per-
fusion parameters (pretreatment tumor permeability surface,
posttreatment mean transit time, percent reduction in BF, and
percent reduction in blood volume) were significantly associ-
ated with best percent reduction in tumor diameters [88]. Tak-
en together, these data suggest that perfusion CT parameters
could potentially become useful surrogate markers for early
response assessment to novel angiogenesis inhibitors in NETs.
Figure 5 illustrates an example of tumor perfusion changes
assessed by DCE-CT induced by antiangiogenic therapy.
DECT provides a new parameter, the iodine uptake, which
is assumed to reflect vital tumor burden by measuring the
iodine uptake of active tumor. Iodinated contrast medium in
lesions is mainly related to blood perfusion of viable tumor.
This biological-related information could be a promising tool
for evaluating tumor response [89] and would be of particular
Fig. 4 Perfusion CT images in a
patient with NET liver
metastases. Conventional CT
image depicts a hypervascular
liver metastasis in the left liver
lobe (white arrows). Parametric
maps of blood flow (BF),
permeability (PS), and time to
peak (TTP) show a different
functional behavior at the
periphery of the metastatic
deposit (black arrows) compared
to normal liver or the center of the
metastasis, with increasing BF
and PS and decreasing TTP.
Perfusion CT provides additional
information compared to
morphologic imaging that may
have prognostic value or be useful
in tumor response evaluation
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interest to assess response to antiangiogenic agents. However,
to our knowledge, there are no published data concerning the
use of this technique in GEP-NETs.
DCE-MRI allows the calculation of quantitative perfusion
parameters by using a rapid series of T1-weighted images to
observe the passage of contrast media intravascularly and as it
leaks into the extravascular space. These pharmacokinetic pa-
rameters include the volume of extravascular space, the trans-
fer constant (Ktrans), and the constant of return (kep), some of
which are of difficult physiological interpretation. Ktrans, for
example, is a parameter that depends on the equilibrium be-
tween BF and the vascular network permeability. Low kep and
Ktrans values can indicate low perfusion, low permeability,
and/or a small blood vessel surface area. Thus, any observed
reductions in these parameters would reflect decreased blood
flow and permeability in tumor lesions, which would be an
indicator of therapeutic success. Miyazaki et al. [79] found
that a lower pretreatment distribution volume and a high arte-
rial flow fraction on baseline DCE-MRI were associated with
a better response to treatment with radiolabeled octreotide
therapy in patients with GEP-NET liver metastasis. Moreover,
tumor and whole-liver distribution volume significantly in-
creased after treatment in responding patients, suggesting that
DCE-MRI could be a useful tool for predicting and monitor-
ing response to PRRT in these patients. By contrast, baseline
radiological patterns assessed by conventional imaging proce-
dures (CT or MRI) did not predict response to yttrium-90
radioembolization in patients with GEP-NET liver metastasis
[90]. However, DCE-MRI has poor intrapatient reproducibil-
ity, particularly in liver metastases [91]. Finally, one major
Fig. 5 Perfusion CT images in a
patient with liver metastases from
a neuroendocrine tumor pre- and
posttherapy using antiangiogenic
drugs. Parametric maps of blood
flow and permeability
superimposed over conventional
CT images. Pretherapy study (a)
demonstrated increased mean
values of blood flow (115 mL/
min/100 g) and permeability
(51 mL/min/100 g), mainly at the
periphery of the metastatic
deposit. Posttherapy exam (b)
evidenced a clear tumor response
with drastic decrease of the values
of both parameters (blood flow=
12 mL/min/100 g and
permeability=12 mL/min/100 g)
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limitation common to all DCE-based imaging modalities is
that they only assess one or a few selected targets, which
may not adequately represent the global tumor behavior, par-
ticularly in a setting of frequent tumor heterogeneity.
Another functional imaging technique increasingly being
used is diffusion-weighted MRI (DW-MRI), which is based
on the microscopic mobility of water molecules owing to ther-
mal agitation. Water diffusion is basically restricted by inter-
actions with cell membranes and macromolecules, and there is
an inverse correlation between the degree of water motion and
tissue cellularity and cell membrane integrity [70]. Thus, DW-
MRI provides insight into cellular architecture at the millime-
ter scale, through a quantitative measurement of water diffu-
sivity, called the apparent diffusion coefficient (ADC). The
biological premise is that malignant tissues generally demon-
strate higher cellularity, tissue disorganization, and increased
extracellular space tortuosity, all of which contribute to a re-
duced motion of water, resulting in lower ADC values in
malignant tumors compared with normal tissues [70]. The
diagnostic superiority of DW-MRI over morphological tech-
niques in a wide range of malignancies has led to the imple-
mentation of this fast sequence in all MRI exams in routine
clinical practice.
DW-MRI is clinically useful at all stages in patients with
GEP-NETs, including detection (Fig. 6), tumor characteriza-
tion, staging, and therapy response assessment. The fusion of
DW images with high b value (a factor that reflects the
strength and timing of the gradients used to generate DW
images) and T2-weighted MRI images improves the identifi-
cation of pancreatic NETs [92, 93], especially in patients with
small isointense lesions observed on conventional MRI se-
quences [94]. Moreover, DW-MRI and ADC maps can pro-
vide information that is useful for differentiating typical and
atypical hemangiomas from other hypervascular liver lesions,
including GEP-NET metastases [95]. An emerging clinical
application of DW-MRI is the whole-body diffusion (WBD)
technique for evaluating the extent of disease. A comparative
study of 68Ga-PET/CT versus WBD showed the overall
superiority of 68Ga-PET/CT for patient staging, particularly
for detecting lymph node and lung tumor deposits, whereas
WBD was more accurate in detecting liver and bone metasta-
ses [96]. DW-MRI is also a valuable tool for assessing tumor
aggressiveness [97, 98]. As an example, Wang et al. [97]
found a significant inverse correlation between ADC values
and tumor cellularity or Ki-67 proliferative index, and this
may thus help to predict the growth rate of endocrine tumors.
Regarding the potential role of DW-MRI for predicting or
monitoring response to therapy, it is important to note that
changes observed in functional imaging appearance may sub-
stantially differ depending on the specific mechanism of ac-
tion of each treatment modality and the effect it induces in
tumors [71]. Treatments that cause apoptosis (e.g., chemother-
apy) result in transitory increased ADC values because of cell
swelling, tumor lysis, and necrosis, although ADC values may
eventually decrease as a result of tissue dehydration and fibro-
sis following cell death. By contrast, antiangiogenic therapies
induce an initial and transient decrease in ADC values proba-
bly owing to reductions in tumor perfusion and in the
extravascular-extracellular space resulting from vascular nor-
malization and decreased vascular permeability [99]. Never-
theless, the opposite effect (ADC increase) may be observed if
significant tumor necrosis is induced by vascular-targeted
therapies. The complexity of interpreting DW-MRI changes
induced by treatment is illustrated in a study conducted by
Wulfert et al. [100]. In this work, DW-MRI and 68Ga-
DOTA-TOC-PET/CT images were acquired before and
3 months after one to two cycles of intra-arterial 90Y-/177Lu-
DOTA-TOC therapy in 14 patients with hepatic metastases
from GEP-NET. High baseline SUVmax values in
68Ga-
DOTA-TOC-PET and ADC mean values in DW-MRI were
both associated with improved response to PRRT. A decrease
in SUVmax in
68Ga-PET was observed only in responding
lesions after one to two cycles of therapy. In contrast, mean
ADC values significantly increased after treatment in both
responding and nonresponding lesions. Nevertheless,
nonresponding lesions with increased ADC values on first
Fig. 6 Diffusion-weighted MRI (DW-MRI) of the pancreas. a Axial
HASTE T2-weighted image does not depict any abnormality in the
uncinate process of the pancreas. b DW image (left) at high b value (b=
1000 s/mm2) and fused image (right) superimposing axial T2-weighted
MRI image and color-coded map derived from high b value (b=1000 s/
mm2) DW image clearly demonstrate a small pancreatic neuroendocrine
tumor (arrows) with restricted diffusion at this level
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follow-up assessment were more likely to achieve a decrease
in size with longer follow-up.
Locoreg iona l therap ies , such as t ransar te r ia l
chemoembolization, may also cause an early reduction in
ADC values after therapy (within the first few hours), after
which consistent increases in ADC values usually occur, co-
inciding with the development of cystic and necrotic changes
[99, 101]. In the field of GEP-NETs, Gowdra Halappa et al.
[102] showed a significant increase in mean volumetric ADC
(27 %, p<0.0001) in all patients with neuroendocrine liver
metastases receiving intra-arterial therapy (chemo- or
radioembolization), 3–4 weeks after therapy. In this study, a
significant response assessed by DW-MRI (defined as an in-
crease of at least 15 % in volumetric ADC) or by DCE-MRI
(defined as a decrease of at least 25 % in volumetric enhance-
ment in the arterial phase or a decrease of at least 50 % in
volumetric enhancement in the venous phase) correlated with
improved survival. By contrast, the response assessed using
RECIST, mRECIST, and EASL criteria did not correlate with
survival. Patients who presented a response only by DW-MRI
(ADC) or DCE-MRI (volumetric tumor enhancement) had a
similar outcome in terms of survival than those who showed a
response using both imaging modalities [102].
Functional imaging is consequently a promising tool for
evaluating GEP-NETs. Most studies performed to date, how-
ever, have been retrospective and have involved small hetero-
geneous patient populations. Important efforts for improving
technical qualification and standardization are certainly war-
ranted before any of the parameters evaluated by functional
imaging can be accepted as surrogate biomarkers for response
assessment in standard practice. Although these techniques
can be performed on standard clinical systems, they require
strict protocols, careful acquisition, accurate contrast-agent
dosing and injection rate, image timing, and image analysis
for quantification. The standardization of these issues is essen-
tial to guarantee reproducibility [103]. The time course and the
type of tumor changes induced must be further defined for the
entire range of individual therapies or treatment strategies, as
well as the magnitude of treatment-induced effects that actu-
ally result in patient benefit. Large prospective validation stud-
ies must also be conducted before these techniques can assist
clinicians in decision-making in current clinical practice.
4 Conclusions and future perspectives
As molecular pathways governing NET cancer development
and progression are being unraveled, and new anticancer
agents targeting specific genomic abnormalities continue to
expand, criteria and technology employed to evaluate drug
antitumor activity need to evolve to accurately assess tumor
response and adequately address whether individual patients
benefit or not from specific therapies. Significant advances in
molecular and functional imaging techniques have provided
new evaluation parameters that may potentially improve re-
sponse assessment to novel therapeutic approaches. These en-
deavors are particularly relevant in the field of NETs, com-
monly slow-growing tumors in which major tumor shrinkages
are unlikely to happen. Optimization of these measures to
monitor response and anticipate the emergence of tumor resis-
tance leading to uncontrolled tumor growth is a major focus of
research. Standardization and validation of these novel tech-
niques and assessment criteria in prospective clinical trials, to
ensure results are reliable and reproducible, are essential be-
fore their widespread use in everyday clinical practice.
Finally, malignant tumors exhibit major phenotypic differ-
ences that can be visualized noninvasively by medical imag-
ing. Innovations in medical devices (hardware) and image
analysis (software) are moving the field toward quantitative
imaging and shall likely improve the ability to evaluate tumor
heterogeneity, a characteristic that has been linked to more
aggressive tumor behavior (e.g., resistance to treatment and
development of metastases) [104]. Radiomics, or the high-
throughput extraction of large numbers of image-based fea-
tures, is certainly an exciting field in development that may
potentially be correlated to genomic and proteomic patterns
[105, 106]. The ability of imaging to quantify the spatial var-
iation in architecture and function of individual tumors will
likely become an essential tool for physicians to make thera-
peutic decisions in the near future.
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